69 Views | 24 Downloads
Ursula J. Buchholz, phone: (301) 594 1533. Email: ubuchholz@niaid.nih.gov
Cyril Le Nouën, phone: (240) 669 5907. Email: lenouenc@niaid.nih.gov
Conceptualization: H.-S.P., X.L., Y.M., C.LN, and U.J.B.. Methodology, formal analysis, visualization: H.-S.P., X.L., Y.M., C.S., L.Y., C.L., I.N.M., P.Z., P.L., C.LN and U.J.B.. Investigation: H.-S.P., X.L., Y.M., C.S., L.Y., C.L., I.N.M., P.Z., P.L., and C.LN.. Resources: R.J., N.L.G., and S.M.B.. Writing – Original Draft: X.L., H.-S.P., C.LN. and U.J.B.. Writing – Review and Editing: All authors.
The authors thank the staff of the NIAID Comparative Medicine Branch for animal study support. We thank Barney Graham and Kizzmekia Corbett, Vaccine Research Center, NIAID, NIH, and Jason McLellan, University of Texas, Austin, TX, for providing plasmid 2019-nCoV S-2P_dFurin_F3CH2S encoding the prefusion-stabilized version of the SARS-CoV-2 S ectodomain which was used to generate ELISA antigen for our studies. The SARS-CoV-2 S protein containing the receptor-binding domain (RBD) was obtained from David Veesler through BEI Resources, NIAID, NIH. We thank Ruturaj Masvekar and Bibi Bielekova, Laboratory of Clinical Immunology & Microbiology, NIAID, NIH for their help with the MSD plate reader.
U.J.B., C.L., X.L, and C.LN. are inventors on the provisional patent application number 63/180,534, entitled “Recombinant chimeric bovine/human parainfluenza virus 3 expressing SARS-CoV-2 spike protein and its use”, filed by the United States of America, Department of Health and Human Services.
This research was supported by the Intramural Research Program of the NIAID, NIH (Project number ZIA AI001298–01).